详情页

当前位置：首页 > 详情页

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

0| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究单位： [1]Beijing Shenogen Biomedical Co., Ltd [2]Eastern Theater General Hospital,QinHuai District Medical Area [3]Peking University Cancer Hospital & Institute [4]Chinese PLA General Hospital [5]Beijing Hospital [6]General Hospital of Chinese Armed Police Forces [7]Guang'anmen Hospital of China Academy of Chinese Medical Sciences [8]Jinan Central Hospital [9]Linyi Cancer Hospital [10]The First Affiliated Hospital of Anhui Medical University [11]Anhui Provincial Hospital [12]The First Affiliated Hospital with Nanjing Medical University [13]The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China [14]Nanfang Hospital of Southern Medical University [15]First People's Hospital of Foshan [16]Affiliated Cancer Hospital & Institute of Guangzhou Medical University [17]Tianjin Medical University Cancer Institute and Hospital [18]The Fourth Hospital of Hebei Medical University [19]Hunan Cancer Hospital [20]The First Hospital of Jilin University [21]307 Hospital of PLA [22]Fudan University [23]Henan Cancer Hospital [24]Jilin Provincial Tumor Hospital [25]First Affiliated Hospital of Harbin Medical University [26]First Affiliated Hospital Bengbu Medical College [27]The First Affiliated Hospital of Soochow University [28]Tongji Hospital [29]Beijing YouAn Hospital [30]Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究目的：

The primary efficacy index of this study is to compare the OS of the two groups.